RUBY · Rubius Therapeutics Inc

-

Please sign in to comment on RUBY

1 Comment

Admin

4 years ago

Rubius Therapeutics, Inc is currently in a long term uptrend where the price is trading 58.7% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Rubius Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 8.8% to $-41M since the same quarter in the previous year.

Finally, its free cash flow grew by 25.3% to $-32M since the same quarter in the previous year.

Based on the above factors, Rubius Therapeutics, Inc gets an overall score of 4/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	PINK
CurrencyCode	USD
ISIN	US78116T1034

Market Cap	5M
PE Ratio	None
Target Price	1
Beta	2.21
Dividend Yield	None

ABOUT

Rubius Therapeutics Inc

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

RUBY · Rubius Therapeutics Inc

-

Rubius Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Rubius Therapeutics Inc using a moving average strategy